Cargando…

Improving outcomes in germ cell cancers using miRNA

Owing to advances in treatment paradigms across the last five decades, testicular cancer is now eminently curable. However, current serum tumour and imaging biomarkers lack adequate sensitivity, specificity, and predictive value. Subsequently, their utility in detecting active malignancy and informi...

Descripción completa

Detalles Bibliográficos
Autores principales: Conduit, Ciara, Tran, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252353/
https://www.ncbi.nlm.nih.gov/pubmed/34262617
http://dx.doi.org/10.1177/17588359211027826
_version_ 1783717281112522752
author Conduit, Ciara
Tran, Ben
author_facet Conduit, Ciara
Tran, Ben
author_sort Conduit, Ciara
collection PubMed
description Owing to advances in treatment paradigms across the last five decades, testicular cancer is now eminently curable. However, current serum tumour and imaging biomarkers lack adequate sensitivity, specificity, and predictive value. Subsequently, their utility in detecting active malignancy and informing treatment decisions is minimal in a large proportion of men with testicular cancer. Micro-ribonucleic acids (miRNA), pertinently miR-371a-3p, offer a new tool, which based on early data, appears to fill many of the gaps that existing biomarkers leave. This paper reviews the evolution of the technology, potential limitations, and discusses the clinical relevance of miRNA as it moves towards the clinic.
format Online
Article
Text
id pubmed-8252353
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82523532021-07-13 Improving outcomes in germ cell cancers using miRNA Conduit, Ciara Tran, Ben Ther Adv Med Oncol Review Owing to advances in treatment paradigms across the last five decades, testicular cancer is now eminently curable. However, current serum tumour and imaging biomarkers lack adequate sensitivity, specificity, and predictive value. Subsequently, their utility in detecting active malignancy and informing treatment decisions is minimal in a large proportion of men with testicular cancer. Micro-ribonucleic acids (miRNA), pertinently miR-371a-3p, offer a new tool, which based on early data, appears to fill many of the gaps that existing biomarkers leave. This paper reviews the evolution of the technology, potential limitations, and discusses the clinical relevance of miRNA as it moves towards the clinic. SAGE Publications 2021-06-30 /pmc/articles/PMC8252353/ /pubmed/34262617 http://dx.doi.org/10.1177/17588359211027826 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Conduit, Ciara
Tran, Ben
Improving outcomes in germ cell cancers using miRNA
title Improving outcomes in germ cell cancers using miRNA
title_full Improving outcomes in germ cell cancers using miRNA
title_fullStr Improving outcomes in germ cell cancers using miRNA
title_full_unstemmed Improving outcomes in germ cell cancers using miRNA
title_short Improving outcomes in germ cell cancers using miRNA
title_sort improving outcomes in germ cell cancers using mirna
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252353/
https://www.ncbi.nlm.nih.gov/pubmed/34262617
http://dx.doi.org/10.1177/17588359211027826
work_keys_str_mv AT conduitciara improvingoutcomesingermcellcancersusingmirna
AT tranben improvingoutcomesingermcellcancersusingmirna